Severe symptomatic aortic stenosis: medical therapy and transcatheter aortic valve implantation (TAVI)- a real-world retrospective cohort analysis of outcomes and cost-effectiveness using national data

Freeman, Phillip Michael, Protty, Majd B., Aldalati, Omar, Lacey, Arron, King, William, Anderson, Richard and Smith, Dave 2016. Severe symptomatic aortic stenosis: medical therapy and transcatheter aortic valve implantation (TAVI)- a real-world retrospective cohort analysis of outcomes and cost-effectiveness using national data. Open Heart 3 (1) , e000414. 10.1136/openhrt-2016-000414

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (794kB) | Preview

Abstract

Objectives: Determine the real-world difference between 2 groups of patients with severe aortic stenosis and similar baseline comorbidities: surgical turn down (STD) patients, who were managed medically prior to the availability of transcatheter aortic valve implantation (TAVI) following formal surgical outpatient assessment, and patients managed with a TAVI implant. Design: Retrospective cohort study from real-world data. Setting: Electronic patient letters were searched for patients with a diagnosis of severe aortic stenosis and a formal outpatient STD prior to the availability of TAVI (1999–2009). The second group comprised the first 90 cases of TAVI in South Wales (2009 onwards). 2 years prior to and 5 years following TAVI/STD were assessed. Patient data were pseudoanonymised, using the Secure Anonymized Information Linkage (SAIL) databank, and extracted from Office National Statistics (ONS), PatientEpisode Database for Wales (PEDW) and general practitioner databases. Population: 90 patients who had undergone TAVI in South Wales, and 65 STD patients who were medically managed. Main outcome measures: Survival, hospital admission frequency and length of stay, primary care visits, and cost-effectiveness. Results: TAVI patients were significantly older (81.8 vs 79.2), more likely to be male (59.1% vs 49.3%), baseline comorbidities were balanced. Mortality in TAVI versus STD was 28% vs 70% at 1000 days follow-up. There were significantly more hospital admissions per year in the TAVI group prior to TAVI/STD (1.5 (IQR 1.0– 2.4) vs 1.0 IQR (0.5–1.5)). Post TAVI/STD, the TAVI group had significantly lower hospital admissions (0.3 (IQR 0.0–1.0) vs 1.2 (IQR 0.7–3.0)) and lengths of stay (0.4 (IQR 0.0–13.8) vs 11.0 (IQR 2.5–28.5), p<0.05). The incremental cost-effectiveness ratio (ICER) for TAVI was £10 533 per quality-adjusted life year (QALY). Conclusions: TAVI patients were more likely to survive and avoid hospital admissions compared with the medically managed STD group. The ICER for TAVI was £10 533 per QALY, making it a cost-effective procedure.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RA Public aspects of medicine
Publisher:	BMJ Publishing Group
ISSN:	2053-3624
Date of First Compliant Deposit:	30 May 2017
Date of Acceptance:	3 May 2016
Last Modified:	13 May 2023 23:12
URI:	https://orca.cardiff.ac.uk/id/eprint/100991

Citation Data

Cited 15 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item